Werewolf Therapeutics Analyst Ratings
Werewolf Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/19/2023 | 514.75% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 09/15/2023 | 514.75% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 08/24/2023 | 268.85% | Wedbush | → $9 | Initiates Coverage On | → Outperform |
| 08/10/2023 | 514.75% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 05/25/2023 | 240.16% | EF Hutton | → $8.3 | Assumes | → Buy |
| 05/12/2023 | 309.84% | B of A Securities | $9 → $10 | Maintains | Buy |
| 05/11/2023 | 514.75% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 03/24/2023 | 240.16% | EF Hutton | → $8.3 | Reiterates | → Buy |
| 03/23/2023 | 268.85% | B of A Securities | → $9 | Reiterates | Buy → Buy |
| 03/23/2023 | 514.75% | HC Wainwright & Co. | $20 → $15 | Reiterates | → Buy |
| 02/27/2023 | 240.16% | EF Hutton | → $8.3 | Reiterates | → Buy |
| 02/17/2023 | 240.16% | EF Hutton | → $8.3 | Reiterates | → Buy |
| 01/30/2023 | 227.87% | B of A Securities | $9 → $8 | Maintains | Buy |
| 12/05/2022 | 240.16% | EF Hutton | → $8.3 | Initiates Coverage On | → Buy |
| 06/02/2022 | 719.67% | HC Wainwright & Co. | → $20 | Assumes | → Buy |
| 05/11/2022 | 596.72% | SVB Leerink | $18 → $17 | Maintains | Outperform |
| 11/19/2021 | 1047.54% | SVB Leerink | $29 → $28 | Maintains | Outperform |
| 09/10/2021 | 965.57% | B of A Securities | → $26 | Initiates Coverage On | → Buy |
| 05/25/2021 | 842.62% | Evercore ISI Group | → $23 | Initiates Coverage On | → Outperform |
| 05/25/2021 | 1088.52% | SVB Leerink | → $29 | Initiates Coverage On | → Outperform |
| 05/25/2021 | 801.64% | Jefferies | → $22 | Initiates Coverage On | → Buy |
| 05/25/2021 | 1211.48% | HC Wainwright & Co. | → $32 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023/09/19 | 514.75% | HC Wainwright公司 | →$15 | 重申 | 購買→購買 |
| 2023/09/15 | 514.75% | HC Wainwright公司 | →$15 | 重申 | 購買→購買 |
| 2023年08月24日 | 268.85% | 韋德布什 | →$9 | 開始承保 | →跑贏大盤 |
| 2023年08月10日 | 514.75% | HC Wainwright公司 | →$15 | 重申 | 購買→購買 |
| 2023年05月25日 | 240.16% | EF Hutton | →$8.3 | 假設 | →購買 |
| 2023年05月12日 | 309.84% | B of A證券 | $9→$10 | 維護 | 買 |
| 2023年05月11日 | 514.75% | HC Wainwright公司 | →$15 | 重申 | 購買→購買 |
| 03/24/2023 | 240.16% | EF Hutton | →$8.3 | 重申 | →購買 |
| 03/23/2023 | 268.85% | B of A證券 | →$9 | 重申 | 購買→購買 |
| 03/23/2023 | 514.75% | HC Wainwright公司 | $20→$15 | 重申 | →購買 |
| 02/27/2023 | 240.16% | EF Hutton | →$8.3 | 重申 | →購買 |
| 02/17/2023 | 240.16% | EF Hutton | →$8.3 | 重申 | →購買 |
| 2023年1月30日 | 227.87% | B of A證券 | $9→$8 | 維護 | 買 |
| 12/05/2022 | 240.16% | EF Hutton | →$8.3 | 開始承保 | →購買 |
| 06/02/2022 | 719.67% | HC Wainwright公司 | →$20 | 假設 | →購買 |
| 2022年05月11日 | 596.72% | SVB Leerink | $18→$17 | 維護 | 跑贏大盤 |
| 2021年11月19日 | 1047.54% | SVB Leerink | $29→$28 | 維護 | 跑贏大盤 |
| 09/10/2021 | 965.57% | B of A證券 | →$26 | 開始承保 | →購買 |
| 2021/05/25 | 842.62% | Evercore ISI集團 | →$23 | 開始承保 | →跑贏大盤 |
| 2021/05/25 | 1088.52% | SVB Leerink | →$29 | 開始承保 | →跑贏大盤 |
| 2021/05/25 | 801.64% | 傑富瑞 | →$22 | 開始承保 | →購買 |
| 2021/05/25 | 1211.48% | HC Wainwright公司 | →$32 | 開始承保 | →購買 |
What is the target price for Werewolf Therapeutics (HOWL)?
狼人治療公司(Howl)的目標價格是多少？
The latest price target for Werewolf Therapeutics (NASDAQ: HOWL) was reported by HC Wainwright & Co. on September 19, 2023. The analyst firm set a price target for $15.00 expecting HOWL to rise to within 12 months (a possible 514.75% upside). 14 analyst firms have reported ratings in the last year.
狼人治療公司(納斯達克：HOWL)的最新目標價是由HC Wainwright&Co.於2023年9月19日報道的。這家分析公司將目標價定為15美元，預計Howl將在12個月內上升(可能上漲514.75%)。過去一年，有14家分析公司公佈了評級。
What is the most recent analyst rating for Werewolf Therapeutics (HOWL)?
狼人治療公司(Howl)的最新分析師評級是多少？
The latest analyst rating for Werewolf Therapeutics (NASDAQ: HOWL) was provided by HC Wainwright & Co., and Werewolf Therapeutics reiterated their buy rating.
狼人治療公司(納斯達克代碼：HOWL)的最新分析師評級是由HC Wainwright&Co.提供的，狼人治療公司重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Werewolf Therapeutics (HOWL)?
狼人治療公司(Howl)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Werewolf Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Werewolf Therapeutics was filed on September 19, 2023 so you should expect the next rating to be made available sometime around September 19, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與狼人治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。狼人治療公司的上一次評級是在2023年9月19日提交的，所以你應該預計下一次評級將在2024年9月19日左右的某個時候提供。
Is the Analyst Rating Werewolf Therapeutics (HOWL) correct?
分析師對狼人治療公司(Howl)的評級正確嗎？
While ratings are subjective and will change, the latest Werewolf Therapeutics (HOWL) rating was a reiterated with a price target of $0.00 to $15.00. The current price Werewolf Therapeutics (HOWL) is trading at is $2.44, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的狼人治療(HOWL)評級被重申，目標價在0.00美元到15.00美元之間。狼人治療公司(Howl)目前的交易價格為2.44美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。